UTP21 Antibody

What is UTP21 and what are its known aliases?

UTP21 is a member of the WD repeat protein family involved in the biogenesis of the small ribosomal subunit. It is also known as WDR36 (WD repeat domain 36), with additional synonyms including GLC1G, TA-WDRP, and TAWDRP. The protein plays a critical role in cellular processes related to ribosome assembly . Mutations in the human homolog WDR36 have been associated with glaucoma, highlighting its clinical relevance beyond basic cellular functions .

What types of UTP21 antibodies are commercially available?

The primary commercially available antibodies for UTP21/WDR36 detection are polyclonal antibodies. These include:

These antibodies target different epitopes of UTP21/WDR36 and are validated for specific applications including immunohistochemistry (IHC), western blotting (WB), and immunofluorescence (IF) .

What species reactivity is available for UTP21 antibodies?

Most commercially available UTP21/WDR36 antibodies have been validated for human samples. While the WDR36 gene is conserved across species including mouse (Wdr36), rat (Wdr36), and bovine models, researchers working with non-human models should verify cross-reactivity with their specific species of interest before proceeding with experiments .

What is the optimal protocol for UTP21 antibody-based Western blotting?

For optimal Western blotting detection of UTP21:

• Sample preparation: Disrupt cells in lysis buffer containing 20 mM Tris (pH 7.5), 100 mM KCl, 5 mM MgCl₂, and protease inhibitors.

• Gel electrophoresis: Separate proteins on a 7.5% SDS-polyacrylamide gel, which is suitable for larger proteins like UTP21.

• Transfer: Transfer proteins to nitrocellulose membrane using standard protocols.

• Blocking: Block membrane with appropriate blocking buffer to reduce non-specific binding.

• Primary antibody: Incubate with anti-UTP21/WDR36 antibody at manufacturer-recommended dilution.

• Detection: Use chemiluminescence-based detection following secondary antibody incubation.

For alternative sample preparation, cells can be resuspended in cold phosphate-buffered saline containing 1 mM phenylmethylsulfonylfluoride and disrupted with glass beads in the presence of SDS and Triton X-100 .

How can I isolate UTP21 protein complexes for study?

To isolate UTP21 complexes using tandem affinity purification (TAP):

• Express TAP-tagged UTP21 in appropriate cells (e.g., utp21::MET2 cells expressing pRS414 ADHUTP21).

• Grow cells to an OD₆₀₀ of approximately 2.0.

• Disrupt cells in lysis buffer (20 mM Tris, pH 7.5, 100 mM KCl, 5 mM MgCl₂, plus protease inhibitors) using glass beads.

• Incubate yeast lysate with IgG sepharose for 1 hour at 4°C.

• Wash with 20 mM Tris-HCl pH 7.5, 100 mM KCl, 5 mM MgCl₂, 0.1% Tween-20.

• Elute proteins bound to IgG sepharose by boiling in SDS-PAGE sample buffer.

• Separate by gel electrophoresis and analyze by immunoblotting with appropriate antibodies .

What controls should I include when using UTP21 antibodies for immunoprecipitation?

When conducting immunoprecipitation experiments with UTP21 antibodies, include these essential controls:

• Input control: Analyze a portion of pre-IP lysate to confirm target protein expression.

• Negative control: Use non-specific IgG of the same species as the UTP21 antibody.

• RNase treatment control: Since UTP21 is involved in RNA processing, include parallel samples with RNase A treatment (10μg/ml) to distinguish direct protein-protein interactions from RNA-mediated associations .

• Wild-type vs. mutant controls: If studying specific UTP21 mutations, include wild-type UTP21 as a comparative control.

• Secondary detection controls: Use appropriate antibodies against expected interaction partners (e.g., Hsp90, Sti1) in immunoblotting .

How can I investigate UTP21 interactions with molecular chaperones?

UTP21 has been identified as a potential Hsp90 client protein. To investigate this interaction:

• Co-immunoprecipitation: Use antibodies against either UTP21 or Hsp90 to pull down protein complexes, followed by immunoblotting for the reciprocal protein.

• Genetic approaches: Combine UTP21 mutations (e.g., utp21-S602F) with temperature-sensitive hsp90 mutations to observe synthetic growth defects.

• Pharmacological inhibition: Treat cells with Hsp90 inhibitors and monitor effects on UTP21 stability and function.

• Steady-state level analysis: Measure UTP21 levels via immunoblotting in wildtype cells versus cells with Hsp90 mutations or under Hsp90 inhibition.

Research has shown that mutation or inhibition of Hsp90 results in reduced steady-state levels of wild-type UTP21, which is characteristic of Hsp90 client proteins .

How do UTP21 mutations affect its detection and function?

Several mutations in UTP21 have been studied, including those analogous to glaucoma-associated alleles in human WDR36:

• UTP21 mutants (R495Q, I567V, D621G, H172P, N317S, L5P) generally express at similar levels as wild-type UTP21 in cells with normal Hsp90 function.

• When combined with Hsp90 mutations (e.g., hsp90-G309S or hsp90-F345A), certain UTP21 mutants show significantly reduced steady-state levels:

  • UTP21-N317S, -I567V and -D621G show the lowest levels in cells with hsp90-G309S.

  • UTP21-I567V and -D621G are significantly affected by the hsp90-F345A mutation.

• Some UTP21 mutations (UTP21-N317S, -I567V and -D621G) also display reduced levels in cells with ydj1-G315E mutation.

These observations suggest that different UTP21 mutations have varying dependencies on chaperone function for stability and proper folding .

What techniques can detect associations between UTP21 and pre-ribosomal particles?

To study UTP21's association with pre-ribosomal particles:

• Sucrose gradient fractionation: Separate ribosomal subunits and pre-ribosomes, followed by immunoblotting with UTP21 antibodies.

• Immunoprecipitation with RNA analysis: Use UTP21 antibodies for IP, then analyze co-precipitated RNAs by northern blotting or RT-PCR.

• Chromatin immunoprecipitation: Determine if UTP21 associates with rDNA.

• Co-localization studies: Perform immunofluorescence with antibodies against UTP21 and nucleolar markers.

• Mass spectrometry: Identify components of UTP21-containing complexes after immunoprecipitation.

Evidence suggests UTP21 is component of pre-ribosomal complexes involved in the biogenesis of the small ribosomal subunit .

How can I troubleshoot weak or absent signals when using UTP21 antibodies?

If experiencing detection issues with UTP21 antibodies:

• Sample preparation: Ensure complete cell lysis and protein extraction with protease inhibitors to prevent degradation.

• Protein concentration: Increase the amount of protein loaded in your assay.

• Antibody conditions: Try higher primary antibody concentrations or extended incubation times.

• Detection sensitivity: Switch to more sensitive detection systems (enhanced chemiluminescence, fluorescent secondary antibodies).

• Expression verification: Confirm UTP21 expression in your sample type, as levels may vary.

• Mutation considerations: If studying mutant forms, be aware that some mutations combined with chaperone defects can reduce steady-state levels significantly .

How can I validate the specificity of a UTP21 antibody?

To validate UTP21 antibody specificity:

• Genetic approaches: Use UTP21 knockdown samples as negative controls (note that complete knockout may not be viable as UTP21 is essential).

• Overexpression controls: Compare detection in cells overexpressing tagged UTP21 versus empty vector controls.

• Peptide competition: Pre-incubate the antibody with the immunizing peptide to block specific binding.

• Multiple antibodies: Use different antibodies targeting distinct UTP21 epitopes and compare detection patterns.

• Molecular weight verification: Confirm the detected band matches UTP21's predicted molecular weight.

• Mass spectrometry: Verify immunoprecipitated protein identity by mass spectrometry.

These validation steps are crucial for ensuring experimental rigor when working with UTP21 antibodies .

How might UTP21 antibodies be useful in glaucoma research?

Given the association between WDR36 (human UTP21 homolog) mutations and glaucoma:

• Mutation analysis: UTP21 antibodies can help assess how glaucoma-associated mutations affect protein expression, stability, and localization.

• Protein interaction studies: Investigate how disease-associated mutations alter interactions with chaperones or other complex components.

• Functional studies: Examine how mutations affect UTP21's role in ribosome biogenesis, potentially contributing to disease pathology.

• Biomarker potential: Evaluate whether WDR36/UTP21 levels or localization patterns could serve as biomarkers for glaucoma progression.

Research has shown that mutations analogous to glaucoma-associated WDR36 alleles (R495Q, I567V, D621G) exhibit enhanced growth defects when combined with chaperone deficiencies, suggesting a potential disease mechanism involving protein folding and stability .

What novel methodologies are emerging for UTP21 antibody applications?

Emerging methodologies for UTP21 antibody applications may include:

• Proximity-based protein interaction techniques: Methods like BioID or APEX labeling combined with UTP21 antibodies for downstream detection.

• Live-cell imaging approaches: Using recently developed antibody-based imaging techniques to track UTP21 dynamics in living cells.

• Single-molecule localization microscopy: Super-resolution techniques to precisely map UTP21 within nucleolar structures.

• Antibody-guided protein engineering: Similar to the DyAb approach described for other proteins, using computational modeling combined with antibody epitope mapping to design improved UTP21 variants for research .

How can I quantify UTP21 expression levels across different experimental conditions?

For accurate quantification of UTP21 expression:

• Use appropriate loading controls (housekeeping proteins) for normalization.

• Employ densitometry software to analyze Western blot band intensities.

• Generate standard curves using recombinant UTP21 protein of known quantities.

• Consider multiple biological and technical replicates to ensure statistical validity.

• When comparing wild-type and mutant UTP21 expression, ensure identical experimental conditions and equal protein loading.

• For experiments involving Hsp90 mutations or inhibitors, include time-course analyses to track UTP21 degradation kinetics.

Research has shown that wild-type UTP21 and UTP21-S602F mutant are expressed at similar steady-state levels under normal conditions, but differential effects emerge under chaperone stress .

How do I interpret data showing differential UTP21 antibody reactivity under various experimental conditions?

When interpreting differential UTP21 antibody reactivity:

• Epitope accessibility: Changes in protein conformation may alter epitope exposure.

• Protein complex formation: UTP21 incorporation into complexes might mask antibody binding sites.

• Post-translational modifications: These could affect antibody recognition.

• Protein stability: Reduced signal could indicate degradation rather than expression changes.

• Cellular localization: Compartmentalization may affect extraction efficiency or accessibility.

For example, research shows that some UTP21 mutants (N317S, I567V, D621G) display significantly reduced levels in cells expressing hsp90-G309S, while other mutants (R495Q, similar to S602F) are less affected by this mutation .